Anzeige
Mehr »
Donnerstag, 02.07.2026 - Börsentäglich über 12.000 News
KI hat das Bohrziel gewählt - startet jetzt die nächste große Kupfer-Story aus Nevada?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
232 Leser
Artikel bewerten:
(1)

Lanas Healthcare Technology Limited: Lanas appoints Rob Hutcheson as Chief Corporate Development Officer to accelerate acquisition strategy

DUBLIN, July 2, 2026 /PRNewswire/ -- Irish-headquartered healthcare technology business, Lanas, has appointed Rob Hutcheson as Chief Corporate Development Officer, strengthening the company's acquisition capabilities as it continues expanding its healthcare technology offering across global markets.

Based in Brisbane, Hutcheson brings more than 20 years' experience in mergers and acquisitions, corporate development and growth strategy, including more than 15 years focused on healthcare technology at PwC and Civica.

The appointment follows Lanas' continued investment in growth since partnering with TA Associates ("TA"), and reflects its long-term strategy of expanding through both product innovation and targeted acquisitions.

In his new role, Hutcheson will lead Lanas' corporate development strategy and M&A team, working closely with founders, management teams and investors to identify complementary healthcare technologies that strengthen the company's capabilities and expand its offering across healthcare in the UK, Ireland, and ANZ.

Lanas is a global healthcare technology company that builds, acquires and scales products used across primary care, community care, pharmacy, specialist care, and care platforms. The company is headquartered in Dublin with customers and operations across the UK, Ireland, Australia and New Zealand.

Howard Beggs, Founder & Chief Executive Officer of Lanas, said Hutcheson's appointment marks an important step in the company's next phase of growth:

"We're building a company focused on the technology healthcare organisations rely on every day.

"Rob brings deep healthcare technology and M&A experience, and he'll play an important role as we continue to strengthen our offering and create greater value for customers.

"We see significant opportunities ahead and are committed to investing in products and capabilities that help make healthcare more connected, efficient and accessible."

Rob Hutcheson said he was attracted by both the strength of Lanas' existing business and the opportunity to help shape its future growth:

"What attracted me to Lanas was the opportunity to join a company with a clear vision and strong foundations.

"The products already support healthcare organisations across multiple markets, and there's a significant opportunity to build on that through disciplined strategic acquisitions.

"I'm looking forward to working with founders, management teams and investors to identify technologies that strengthen our capabilities, expand our offering and help solve real healthcare challenges."

Backed by TA, a leading global private equity firm, Lanas launched in November 2025, with a committed M&A funding packet of €100m.

With over 20 products and services currently serving clinicians across two hemispheres, the company is focused on building, acquiring, scaling, and supporting proven healthcare technologies, with an aim to advance the electronic health record (EHR) market through innovation and operational excellence.

About Lanas

871 million clinical documents and messages flow through our platforms every year. Over 40,000 GPs across two hemispheres start their day using our products. Every second, two prescriptions are processed through a Lanas system.

Lanas is a healthcare technology company focused on making care more efficient for the clinicians who deliver it, and more accessible for the patients who need it. We build, acquire and grow products used across primary care, pharmacy, specialists, and care platforms, supporting the clinical and operational workflows healthcare organisations rely on every day.

Headquartered in Dublin, and operating across the UK, Ireland, Australia and New Zealand, Lanas launched in 2025, backed by TA Associates.

www.lanas.com

Photo: https://mma.prnewswire.com/media/3002508/Rob_Hutcheson_CCDO_Lanas_Healthcare.jpg
Logo: https://mma.prnewswire.com/media/3002507/Lanas_Logo.jpg

Contact:
lauren.turner@lanas.com
communications@lanas.com

Cision View original content:https://www.prnewswire.co.uk/news-releases/lanas-appoints-rob-hutcheson-as-chief-corporate-development-officer-to-accelerate-acquisition-strategy-302816817.html

© 2026 PR Newswire
SpaceX-Hype zu teuer – Diese 5 Aktien bieten bessere Chancen
Raumfahrt-Aktien gehören aktuell zu den heißesten Wetten an den Börsen. Spätestens mit dem spektakulären Börsengang von SpaceX ist der Sektor endgültig im Fokus der Anleger angekommen. Fantasien rund um Satellitenkommunikation, Rechenzentren im All und neue Geschäftsmodelle treiben die Kurse immer weiter nach oben.

Doch während die Begeisterung steigt, werden auch die Risiken größer. Viele Space-Start-ups sind inzwischen extrem hoch bewertet, arbeiten noch nicht profitabel und hängen stark von stetigem Kapitalzufluss ab. Schon kleine Rückschläge könnten die ambitionierten Wachstumspläne ins Wanken bringen.

Für Anleger, die vom Boom der Raumfahrt profitieren wollen, lohnt sich daher ein Perspektivwechsel. Statt auf überhitzte Pure Plays zu setzen, rücken etablierte Konzerne in den Fokus – Unternehmen mit jahrzehntelanger Erfahrung, stabilen Cashflows und engen Verbindungen zu Raumfahrtagenturen wie NASA und ESA.

In unserem aktuellen Spezialreport stellen wir fünf Aktien vor, die genau dieses Profil erfüllen: solide bewertet, operativ stark und bestens positioniert, um langfristig vom Space-Boom zu profitieren.

Jetzt den kostenlosen Report sichern – bevor der Markt die versteckten Gewinner entdeckt!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.